TherapeuticsMD (TXMD) Stock Price, News & Analysis

Company Overview

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Key Stats

• Today's Range: $1.03 to $1.66
• 50-Day Range: $0.86 to $1.57
• 52-Week Range: $0.70 to $2.75
• Volume: 13.98 million shs
• Average Volume: 926,183 shs
• Market Capitalization: $14.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TherapeuticsMD Stock Analysis - MarketRank™

TherapeuticsMD scored higher than 9% of companies evaluated by MarketBeat, and ranked 920th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for TherapeuticsMD.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

TherapeuticsMD has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.53% of the float of TherapeuticsMD has been sold short.

Short Interest Ratio / Days to Cover

TherapeuticsMD has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TherapeuticsMD has recently decreased by 27.64%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TherapeuticsMD does not currently pay a dividend.

Dividend Growth

TherapeuticsMD does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.53% of the float of TherapeuticsMD has been sold short.

Short Interest Ratio / Days to Cover

TherapeuticsMD has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TherapeuticsMD has recently decreased by 27.64%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 3 people have searched for TXMD on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added TherapeuticsMD to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TherapeuticsMD insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.30% of the stock of TherapeuticsMD is held by insiders.

Percentage Held by Institutions

Only 30.74% of the stock of TherapeuticsMD is held by institutions.

TXMD Stock Analysis - Frequently Asked Questions

How have TXMD shares performed this year?

TherapeuticsMD's stock was trading at $0.86 at the beginning of 2025. Since then, TXMD stock has increased by 51.2% and is now trading at $1.30.
View the best growth stocks for 2025 here.

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD, Inc. (NASDAQ:TXMD) announced its earnings results on Tuesday, November, 12th. The company reported ($0.05) earnings per share for the quarter. The firm earned $0.55 million during the quarter. TherapeuticsMD had a negative trailing twelve-month return on equity of 14.08% and a negative net margin of 207.77%.

When did TherapeuticsMD's stock split?

TherapeuticsMD's stock reverse split before market open on Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Who are TherapeuticsMD's major shareholders?

Top institutional shareholders of TherapeuticsMD include Group One Trading LLC, Citadel Advisors LLC and Concourse Financial Group Securities Inc.. Insiders that own company stock include Rubric Capital Management Lp, Marlan D Walker, Cooper C Collins, Michael C Donegan, Brian Bernick and Gail K Naughton.
View institutional ownership trends.

How do I buy shares of TherapeuticsMD?

Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TherapeuticsMD investors own include Voyager Therapeutics (VYGR), Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Marinus Pharmaceuticals (MRNS), AUO (AUOTY) and The RMR Group (RMR).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 2/22/2025
• Next Earnings (Estimated): 4/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TXMD
• Previous Symbol: NYSEMKT:TXMD
• CUSIP: N/A
• CIK: 25743
• Web: www.therapeuticsmd.com
• Phone: (561) 961-1900
• Fax: 561-431-3389
• Employees: 420
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-10,280,000.00
• Net Margins: -207.77%
• Pretax Margin: -251.25%
• Return on Equity: -14.08%
• Return on Assets: -9.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.03
• Quick Ratio: 2.03

Sales & Book Value

• Annual Sales: $1.30 million
• Price / Sales: 11.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.77 per share
• Price / Book: 0.47

Miscellaneous

• Outstanding Shares: 11,530,000
• Free Float: 11,267,000
• Market Cap: $14.99 million
• Optionable: Optionable
• Beta: 1.22